Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/09/2025 07:31 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [05/08/2025 07:16 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [05/05/2025 07:20 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [04/25/2025 07:42 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [04/23/2025 10:29 PDT] Beam Therapeutics Inc. (NASDAQ:BEAM), Up By 100% ($16.62) From $16.62 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/23/2025 10:29 PDT] Beam Therapeutics Inc. (NASDAQ:BEAM), Up By 100% ($17.28) From $17.28 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/17/2025 07:03 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [04/16/2025 07:17 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [04/15/2025 10:29 PDT] Beam Therapeutics Inc. (NASDAQ:BEAM), Up By 100% ($14.63) From $14.63 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/11/2025 07:28 PDT] BEAM Expected to Trade Up After Bullish Patterns Develop
• [04/07/2025 08:09 PDT] BEAM, Expected to Trade Lower After Bearish Insider Trading
• [04/04/2025 10:29 PDT] Beam Therapeutics Inc. (NASDAQ:BEAM), Down By 100% ($17.64) From $17.64 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/02/2025 07:09 PDT] BEAM Expected to Trade Down After Bearish Patterns Develop